Exemestane for breast cancer prevention: a critical shift?

Cancer Discovery
Andrea DecensiLeslie G Ford

Abstract

The Mammary Prevention 3 (MAP.3) placebo-controlled randomized trial in 4,560 high-risk postmenopausal women showed a 65% reduction in invasive breast cancer with the use of exemestane at 35 months median follow-up. Few differences in adverse events were observed between the arms, suggesting a promising risk:benefit balance with exemestane for use in chemoprevention. Yet, the MAP.3 design and implementation raise concerns regarding limited data maturity and not prospectively including key bone-related and other toxicities as study end points. Exemestane for prevention is juxtaposed against selective estrogen receptor modulators and the other aromatase inhibitors. Additional issues for prevention, including the influence of obesity, alternative dosing, and biomarker use in phase III trials, are addressed. The recently completed MAP.3 trial of exemestane for breast cancer prevention offers a potential new standard for pharmaceutical risk reduction in high-risk postmenopausal women. In addition to describing key findings from the publication of MAP.3 and related trials, our review undertakes a detailed analysis of the strengths and weaknesses of MAP.3 as well as the implications for future prevention research.

References

Jan 1, 1988·Journal of Steroid Biochemistry·D GiudiciE di Salle
Oct 1, 1995·British Journal of Cancer·N ZilemboA Laffranchi
Jan 1, 1996·Journal of Cellular Biochemistry. Supplement·G J KelloffC C Sigman
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E BajettaJ Paolini
Apr 1, 1998·Journal of the National Cancer Institute·D HwangE Levine
Apr 1, 1998·American Journal of Epidemiology·C CooperD Coggon
Nov 5, 1999·Journal of the National Cancer Institute·M H GailV Vogel
Dec 3, 1999·BMJ : British Medical Journal·D G Altman, P K Andersen
May 5, 2001·British Journal of Cancer·S A Khuder, A B Mutgi
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rowan T ChlebowskiUNKNOWN American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group
Jun 5, 2003·Journal of the National Cancer Institute·Andrea DecensiUmberto Veronesi
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
Feb 18, 2004·The Breast : Official Journal of the European Society of Mastology·P E Lønning
Aug 3, 2004·Nature Reviews. Cancer·Eugenia E Calle, Rudolf Kaaks
Sep 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul E GossKenneth P H Pritzker
Dec 2, 2004·Journal of the National Cancer Institute·Silvana MartinoUNKNOWN CORE Investigators
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jack Cuzick
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Per E LønningGiorgio Massimini
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco BoccardoPiero Sismondi
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Sherene LoiKelly-Anne Phillips
Dec 31, 2005·The New England Journal of Medicine·UNKNOWN Breast International Group (BIG) 1-98 Collaborative GroupAron Goldhirsch
Jan 19, 2006·JAMA : the Journal of the American Medical Association·Jeffrey S BergerDavid L Brown
Jun 7, 2006·JAMA : the Journal of the American Medical Association·Victor G VogelUNKNOWN National Surgical Adjuvant Breast and Bowel Project (NSABP)
Jun 9, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F BoccardoP Sismondi
Jun 17, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gary J KelloffUNKNOWN AACR Task Force on Cancer Prevention
Aug 5, 2006·The Lancet Oncology·UNKNOWN Arimidex, Tamoxifen, Alone or in Combination Trialists' GroupJ M Nabholtz
Jan 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan S CoatesAron Goldhirsch
Feb 22, 2007·Journal of the National Cancer Institute·Jack CuzickUNKNOWN International Breast Cancer Intervention Study I Investigators
Feb 22, 2007·Journal of the National Cancer Institute·Trevor J PowlesMitch Dowsett
May 2, 2007·Journal of the National Cancer Institute·Umberto VeronesiUNKNOWN Italian Tamoxifen Study Group
Jun 15, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DecensiBernardo Bonanni
Nov 8, 2007·BMJ : British Medical Journal·Gillian K ReevesUNKNOWN Million Women Study Collaboration
Dec 13, 2007·Journal of the National Cancer Institute·Raimund JakeszUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Mar 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriella RondaninaAndrea Decensi
Aug 16, 2008·The Lancet Oncology·Ivana SestakUNKNOWN ATAC Trialists' Group

❮ Previous
Next ❯

Citations

Nov 16, 2012·Nature Reviews. Cancer·Asad UmarPeter Greenwald
Jan 18, 2014·Endocrine-related Cancer·Kathleen Van AstenRobert Paridaens
Apr 5, 2014·Expert Opinion on Pharmacotherapy·Valentina RossiFilippo Montemurro
Mar 29, 2013·The Breast : Official Journal of the European Society of Mastology·Barbara K DunnAndrea DeCensi
May 1, 2012·Seminars in Oncology Nursing·Judith J Smith, Barbara K Dunn
Mar 20, 2016·The Journal of Steroid Biochemistry and Molecular Biology·Ana Filipa SobralNatércia Teixeira
Oct 12, 2012·Annals of the New York Academy of Sciences·Priscilla A Furth
Apr 25, 2014·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Hitomi ShinodaWilliam H Hanneman
May 21, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Suzanne E WardellShunqiang Li
Jul 1, 2020·Anti-cancer Agents in Medicinal Chemistry·Pooja RatreSuresh Thareja

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Therapeutic Advances in Medical Oncology
Jennifer Keating LittonBanu K Arun
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Yang ZhangJill M Kolesar
Current Breast Cancer Reports
Laura Reimers, Katherine D Crew
© 2021 Meta ULC. All rights reserved